Literature DB >> 19571800

Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection.

M Kader1, X Wang, M Piatak, J Lifson, M Roederer, R Veazey, J J Mattapallil.   

Abstract

Human immunodeficiency virus/simian immunodeficiency virus (HIV/SIV) infections are believed to infect minimally activated CD4(+) T cells after viral entry. Not much is known about why SIV selectively targets these cells. Here we show that CD4(+) T cells that express high levels of the alpha4beta7 heterodimer are preferentially infected very early during the course of SIV infection. At days 2-4 post infection, alpha4(+)beta7(hi)CD4(+) T cells had approximately 5x more SIV-gag DNA than beta7(-)CD4(+) T cells. alpha4(+)beta7(hi)CD4(+) T cells displayed a predominantly central memory (CD45RA(-)CD28(+)CCR7(+)) and a resting (CD25(-)CD69(-)HLA-DR(-)Ki-67(-)) phenotype. Although the expression of detectable CCR5 was variable on alpha4(+)beta7(hi) and beta7(-)CD4(+) T cells, both CCR5(+) and CCR5(-) subsets of alpha4(+)beta7(hi) and beta7(-)CD4(+) T cells were found to express sufficient levels of CCR5 mRNA, suggesting that both these subsets could be efficiently infected by SIV. In line with this, we found similar levels of SIV infection in beta7(-)CD4(+)CCR5(+) and beta7(-)CD4(+)CCR5(-) T cells. alpha4beta7(hi)CD4(+) T cells were found to harbor most T helper (Th)-17 cells that were significantly depleted during acute SIV infection. Taken together, our results show that resting memory alpha4(+)beta7(hi)CD4(+) T cells in the blood are preferentially infected and depleted during acute SIV infection, and the loss of these cells alters the balance between Th-17 and Th-1 responses, thereby contributing to disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571800      PMCID: PMC2763371          DOI: 10.1038/mi.2009.90

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  42 in total

1.  Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques.

Authors:  S Kewenig; T Schneider; K Hohloch; K Lampe-Dreyer; R Ullrich; N Stolte; C Stahl-Hennig; F J Kaup; A Stallmach; M Zeitz
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

2.  Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.

Authors:  A Nichole Cline; Julian W Bess; Michael Piatak; Jeffrey D Lifson
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

3.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

Authors:  Qingsheng Li; Lijie Duan; Jacob D Estes; Zhong-Min Ma; Tracy Rourke; Yichuan Wang; Cavan Reilly; John Carlis; Christopher J Miller; Ashley T Haase
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Characterization of gut-associated lymphoid tissue (GALT) of normal rhesus macaques.

Authors:  R S Veazey; M Rosenzweig; D E Shvetz; D R Pauley; M DeMaria; L V Chalifoux; R P Johnson; A A Lackner
Journal:  Clin Immunol Immunopathol       Date:  1997-03

5.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.

Authors:  Joseph J Mattapallil; Daniel C Douek; Brenna Hill; Yoshiaki Nishimura; Malcolm Martin; Mario Roederer
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.

Authors:  M Briskin; D Winsor-Hines; A Shyjan; N Cochran; S Bloom; J Wilson; L M McEvoy; E C Butcher; N Kassam; C R Mackay; W Newman; D J Ringler
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

7.  Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates.

Authors:  E Pesenti; C Pastore; F Lillo; A G Siccardi; D Vercelli; L Lopalco
Journal:  AIDS Res Hum Retroviruses       Date:  1999-07-20       Impact factor: 2.205

8.  Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1.

Authors:  S L Kozak; S E Kuhmann; E J Platt; D Kabat
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

9.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

10.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  109 in total

1.  The Role of Integrin Expressing Cells in Modulating Disease Susceptibility and Progression (January 2016).

Authors:  Aftab A Ansari; Siddappa N Byrareddy
Journal:  Int Trends Immun       Date:  2016-01

2.  Preferential loss of gut-homing α4β7 CD4+ T cells and their circulating functional subsets in acute HIV-1 infection.

Authors:  Xiaofan Lu; Zhen Li; Qunhui Li; Yanmei Jiao; Yunxia Ji; Hongwei Zhang; Zhuoming Liu; Wei Li; Hao Wu
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

Review 3.  The role of Th17 cytokines in primary mucosal immunity.

Authors:  Jay K Kolls; Shabaana A Khader
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-20       Impact factor: 7.638

4.  In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.

Authors:  Yelina Alvarez; Michael Tuen; Arthur Nàdas; Catarina E Hioe
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

5.  The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

Authors:  Claudia Cicala; Elena Martinelli; Jonathan P McNally; Diana J Goode; Ravindra Gopaul; Joseph Hiatt; Katija Jelicic; Shyamasundaran Kottilil; Katilyn Macleod; Angeline O'Shea; Nikita Patel; Donald Van Ryk; Danlan Wei; Massimiliano Pascuccio; Ling Yi; Lyle McKinnon; Preson Izulla; Joshua Kimani; Rupert Kaul; Anthony S Fauci; James Arthos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

Review 6.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

7.  Identification of preferential CD4+ T-cell targets for HIV infection in the cervix.

Authors:  V R Joag; L R McKinnon; J Liu; S T Kidane; M H Yudin; B Nyanga; S Kimwaki; K E Besel; J O Obila; S Huibner; J O Oyugi; J Arthos; O Anzala; J Kimani; M A Ostrowski; R Kaul
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

8.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

9.  Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes.

Authors:  Mahesh Chemudupati; Adam D Kenney; Anna C Smith; Robert J Fillinger; Lizhi Zhang; Ashley Zani; Shan-Lu Liu; Matthew Z Anderson; Amit Sharma; Jacob S Yount
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 10.  Role of the Fas/FasL pathway in HIV or SIV disease.

Authors:  Bhawna Poonia; C David Pauza; Maria S Salvato
Journal:  Retrovirology       Date:  2009-10-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.